Search
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreEHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read more